All In Biotech

NDA 011145 · Rising

Diuril

Chlorothiazide, Chlorothiazide Sodium · Oral, Injection

NovelPriority reviewDiscontinued

Last checked: Nov 20, 2026Latest source record: Mar 20, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1958

Sep 4, 1958

Approved uses

1

Original approval plus efficacy supplements

Registered trials

330

91 Phase 3, 10 recruiting

FAERS reports

1,263

1,011 serious, 199 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 4, 1958 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • DIURIL · CHLOROTHIAZIDE 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • DIURIL · CHLOROTHIAZIDE 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • DIURIL · CHLOROTHIAZIDE SODIUM EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Chlorothiazide" as an intervention, any sponsor and status, largest first.

All 330 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use88
  • dyspnoea81
  • pyrexia79
  • diarrhoea73
  • hypotension71
  • drug ineffective66
  • pneumonia63
  • respiratory failure62
  • pain59
  • vomiting52
  • death50
  • cough48

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200525
200619
200725
200816
200927
201035
201155
201240
201353
201456
201555
201684
201763
2018120
2019107
2020108
202192
202293
202361
202443
202541
202626

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Diuril (Chlorothiazide)

2024 spending

$21K

Beneficiaries

85

236 claims

Per beneficiary

$247

$0.31 per unit

View as table
YearSpending
2020$20,134
2021$24,603
2022$30,867
2023$17,639
2024$20,999

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 50 on PubMed

Sponsor: Rising

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.